Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies

News

Photo of Ash Maroof, Founder and CSO.

RE-AIM Therapeutics: Targeting disease causal cells to cure autoimmunity

We are delighted to welcome RE-AIM Therapeutics to the BioEscalator community, a start-up focused on developing antibody-based curative therapies for inflammatory disorders, such as psoriasis and inflammatory bowel disease.

The BioEscalator welcomes SiGenex to its growing community

SiGenex is advancing genomic medicine with its innovative, artificial intelligence-powered in-hospital sequencing platform. The company's technology is designed to transform how hospitals, clinics, and medical centres perform targeted next-generation sequencing (NGS) tests.

A photo of the Bioarchitech team on their last day in the BioEscalator. Left to right: Ines Loureiro, Kevin Maskell, Andri Vasou, and William Jackson.

Bioarchitech graduates from the BioEscalator: A new chapter for innovative cancer therapy

Bioarchitech, a biotech company specialising in innovative cancer therapies, is about to start a new phase as it leaves the BioEscalator. The company has been based at the BioEscalator since 2019.

Highlights from the 5th annual BioEscalator Pitch Battle 2024

The 5th Annual BioEscalator Pitch Battle was an exciting showcase of fierce competition and groundbreaking innovations. With seven categories, ten companies competing for the top spot, and £2000 in prize money at stake, the judges faced a formidable task in selecting the winners.

Nucleome Therapeutics appoints Mark Bodmer as Chief Executive Officer

Nucleome Therapeutics (‘Nucleome’ or ‘the Company’), a biotechnology company using spatial genomics to discover precision medicines for complex diseases, announces today that it has appointed Dr. Mark Bodmer as Chief Executive Officer with effect from 24 July.

Photo of Moa Technology CEO Dr Virginia Corless.

Moa harvests global deal for new herbicide

Agricultural biotech firm Moa Technology has signed a research and commercial partnership with Nufarm, a global agricultural innovator based in Melbourne, Australia.

Photo: Left to right - Michael Dustin, Professor of Molecular Immunology; Ashwin Jainarayanan, Founder & CSO of Granza Bio; and Ashwin Nandakumar, Founder & CEO of Granza Bio.

Granza Bio grabs $7M seed from Felicis and YC to advance delivery of cancer treatments

In April 2024, the BioEscalator welcomed Granza Bio, a biotech startup focusing on developing novel immunotherapy delivery methods. The company has already attracted investor interest and closed a successful $7.14 million seed funding round led by Felicis and Refactor, with participation from Y Combinator.

A photo of Dr Claire Shingler with a quote that reads: "Working with spin-outs and start-ups is hugely inspiring and rewarding. It is fast-paced, outward-looking, and very collaborative."

Collaboration in action: Academic-industry stories

Our Business Manager, Dr Claire Shingler, participated in a collaborative project highlighting the strong partnerships between academic and industry professionals in the Medical Sciences Division. In this project, Claire shared her story and discussed her role in managing Oxford's biomedical science incubator. She discussed her motivations and the rewarding experiences she has had in supporting innovative spin-outs.

OSPT Ltd brings together ideas and experience for ‘astonishing’ success at the BioEscalator

The idea behind antibacterial company OSPT came to CEO and Co-Founder Stephanie Lesage as she talked to haemodialysis patients as part of a research project, when it became clear to her that they had a really deep fear of the development of infection via their catheters. Their concerns were so significant that they almost outweighed the benefits of the dialysis treatment in the patients’ minds.

GSK enters into a multi-year data licence agreement with Ochre Bio to further investigate the drivers of liver disease

Ochre and GSK will create a foundational liver biology dataset that could have the potential to further improve translation of novel therapies for liver diseases.

MediMabBio's graduation from the BioEscalator: A testament to innovation and growth

MediMab Biotherapeutics announces its graduation from the BioEscalator. This move represents a major milestone for the company as it relocates to Abingdon Science Park, positioning itself for further expansion and cutting-edge research in immuno-oncology.

A timeline of Evolvere Biosciences' progress from winning the OUBT Biohackathon in 2021, to moving into the BioEscalator and receiving the No Limits grant from Innovate UK.

Biohackathons, boot-strapping and Innovate UK backing – how Evolvere Biosciences is tackling antimicrobial resistance

A seminal study in The Lancet¹ estimates that in 2019 some 4.95 million deaths were associated with bacterial AMR, including 1.27 million deaths attributable to bacterial AMR. Evolvere is tackling this challenging unmet need using a platform combining synthetic biology, bioinformatics, and AI, designing new drugs plus generating AI models for other companies to license.

Image: Brad Loncar speaking with Professor Matthew Wood

BiotechTV explores the BioEscalator's role in nurturing start-ups

Brad Loncar visited the BioEscalator to learn more about how we support the growth of innovative medical science companies.

A photo of two Infinitopes scientists working in their laboratory.

Integrated cancer biotech Infinitopes secures £12.8M seed financing to enhance its Precision Immunomics(TM) antigen discovery technologies to target five more cancers

Funding also supports the start of phase I/IIa study for lead vaccine, ITOP1

An image of a memorandum document with the MediMabBio and PDC*line Pharma logo overlaid.

MediMabBio signs MOU with PDC*line Pharma to collaborate on cancer immunotherapy

MediMabBio has announced a new memorandum of understanding (MOU) with PDCline Pharma. This collaboration aims to explore the synergy between MediMabBio's MMB101/MFA011 and PDC*line Pharma’s plasmacytoid dendritic cell (PDC) cancer vaccines to revolutionise cancer treatment. Together, their promising drug candidates, targeting TIGIT and other immuno-oncology pathways, would enhance the efficacy of PDC cancer vaccines. By leveraging PDC*line Pharma’s expertise, MediMabBio aims to boost the efficacy of its therapies and explore innovative treatment strategies.

CardiaTec joins the BioEscalator - AI in cardiovascular drug discovery

The BioEscalator welcomes CardiaTec, a spin-out company from the University of Cambridge that employs computational methods to decode the biology behind cardiovascular disease.

A dotted line connects Seoul, South Korea and Oxford, United Kingdom on a world map.

MediMabBio - Two time zones, one mission

Two clocks are visible behind the Chief Scientific Officer of MediMabBio, Dr Chris Willberg, as he sits in the company office at the BioEscalator – showing time zones seven hours apart, they are a reminder of how teams in Seoul and Oxford are working together to discover new treatments for cancer and autoimmune disease.

Hands putting together a puzzle. The puzzle image is a blue background with the word partnership overlaid.

Exogene announces strategic collaboration with Immunocore to engineer T-Cell receptors using artificial intelligence

Exogene is excited to announce a research collaboration with TCR therapy industry leader Immunocore, developer of a novel class of TCR-based bispecific treatments for oncology, infectious diseases and autoimmune diseases using their proprietary ImmTAX technology. The purpose of the collaboration is to accelerate the discovery of high-affinity TCRs, with a vision to ultimately accelerate the development of TCR-based bispecific therapies across multiple targets and indications.

Granza Bio: Pioneering personalised and targeted cancer therapeutics

The BioEscalator is pleased to welcome Granza Bio, a biotech startup founded by two PhD graduates in oncology and immunology from the University of Oxford. Granza Bio is pioneering a new era in cancer therapeutics by developing personalised and targeted cancer treatments using the body's own immune system.

An illustration of a brainstorm cloud with the Bioarchitech logo in the centre. Three phrases are connected to the cloud by arrows - oncolytic viruses, protein immunotherapy, and improved outcomes for cancer patients representing Bioarchitech's innovative ideas. Next to each phrase is a lightbulb.

It started with a brainstorm

Companies start in all kinds of different ways, and for Bioarchitech it was brainstorming that generated the idea behind the enterprise. It is now planning a Series A fundraising to bring its lead candidate to the clinic. Bioarchitech is focused on cancer, developing oncolytic viruses encoding protein immunotherapies for the destruction of tumours, ideally with just one or two doses.

Load More